U.S. Patent 8,222,244: Midostaurin AML Claims, Patent Scope, Expiration and Generic Risk

U.S. Patent No. 8,222,244 protects methods of treating acute myeloid leukemia with midostaurin, also known as PKC412, when the leukemia has deregulated FLT3 receptor tyrosine kinase activity. The patent does not principally protect the midostaurin molecule itself. Its commercial value is concentrated in AML treatment, dosing, oral administration and selected formulation routes.

The patent issued to Novartis AG on July 17, 2012. Based on its priority and filing history, the ordinary U.S. patent term is expected to extend into March 2027, subject to any applicable patent-term adjustment, terminal disclaimer or patent-term extension reflected in the USPTO and FDA records.[1][2]

What drug does U.S. Patent 8,222,244 cover?

The claimed compound is midostaurin, the active ingredient in Rydapt.

Item	Description
Generic name	Midostaurin
Development code	PKC412
Brand	Rydapt
Drug class	Multikinase inhibitor
Relevant target	FLT3 receptor tyrosine kinase
Other principal activity	Protein kinase C inhibition
Patent holder	Novartis AG
U.S. patent	8,222,244
Issue date	July 17, 2012
Primary protected use	Treatment of AML characterized by deregulated FLT3 activity
FDA AML approval	April 28, 2017
FDA AML population	Newly diagnosed AML with FLT3 mutation, in combination with cytarabine and daunorubicin induction and cytarabine consolidation

The chemical name in the claims identifies midostaurin without using the generic name. The phrase “or a salt thereof” extends the claim to pharmaceutically acceptable salt forms of the specified compound.

What is the scope of claim 1 in U.S. Patent 8,222,244?

Claim 1 is the central method-of-treatment claim. It requires all of the following elements:

A mammal suffering from AML.
Administration of a therapeutically effective amount.
Administration of midostaurin or a salt thereof.
AML characterized by deregulated FLT3 receptor tyrosine kinase activity.

The claim is not limited to a particular age, sex, disease stage or chemotherapy combination. It also does not expressly require newly diagnosed AML, although the FDA-approved AML indication is limited to newly diagnosed FLT3-mutated AML used with standard chemotherapy.[3]

How the FLT3 limitation affects infringement

The FLT3 limitation is material. A method involving midostaurin and AML would not fall within claim 1 unless the AML is characterized by deregulated FLT3 activity.

“Deregulated” is broader than a single named mutation. It may encompass constitutive activation, activating FLT3 mutations, abnormal receptor signaling, overexpression or other forms of abnormal FLT3 kinase activity, depending on claim construction and the supporting specification. The FDA label uses a narrower operational standard based on FLT3 mutation testing, including internal tandem duplication and tyrosine kinase domain mutations.[3]

For patent enforcement, the claim creates a diagnostic linkage:

Midostaurin administration alone is insufficient.
AML alone is insufficient.
The relevant AML must have deregulated FLT3 activity.
The accused conduct must involve a therapeutically effective amount.

A generic manufacturer could face infringement risk if its labeling directs use of midostaurin for FLT3-positive AML. The risk would be greater if the proposed label reproduces Rydapt’s AML indication, dosing or treatment sequence.

How do claims 2 through 6 narrow the patent?

Claims 2 through 6 are dependent claims. Each incorporates every limitation of claim 1 and adds a dosing, route or formulation limitation.

Claim	Added limitation	Commercial significance
1	Midostaurin for AML with deregulated FLT3 activity	Core method claim
2	Repeated treatment cycles, with administration on approximately 100% to 50% of days and treatment pauses	Regimen claim
3	225 mg administered daily	Specific dose claim
4	Oral administration	Route-of-administration claim
5	Microemulsion, soft gel or solid dispersion	Dosage-form claim
6	Microemulsion	Narrowest formulation claim

What is the scope of claim 2?

Claim 2 describes repeated cycles involving one to six weeks of treatment followed by one to three weeks without treatment. It states “7 to 4 times a week,” which is internally unusual because the range is expressed in descending order. The claim also uses “about 100% to about 50% of the days,” corresponding broadly to administration on approximately seven to four days per week.

Potential legal issues include:

Whether “7 to 4 times a week” is indefinite.
Whether “about” provides an objectively determinable range.
Whether “one to several cycles” supplies an adequate boundary.
Whether the specification provides sufficient support for the full dosing range.

A court could construe the language as covering daily, near-daily or intermittent dosing. The wording is vulnerable to an indefiniteness challenge if a skilled person cannot determine the outer limits of the regimen with reasonable certainty under 35 U.S.C. §112(b).[4]

What is the scope of claim 3?

Claim 3 requires administration of 225 mg of midostaurin daily. It is substantially narrower than claim 1.

The approved Rydapt AML regimen is 50 mg twice daily on days 8 through 21 of each chemotherapy cycle, followed by 50 mg twice daily on days 8 through 21 of each consolidation cycle. That equals 100 mg per day, not 225 mg per day.[3]

Claim 3 therefore does not map directly onto the FDA-approved AML dosing schedule. Its commercial value may be limited unless:

225 mg daily was used in clinical development;
a physician uses that dose off label;
a competing product label includes that dose; or
the claim is asserted based on a broader interpretation of daily total dosing or treatment context.

The difference between the patented 225 mg dose and the approved 100 mg daily dose weakens the claim’s direct relevance to the current Rydapt AML label.

What is the scope of claims 4, 5 and 6?

Claim 4 covers oral administration. It does not require a particular tablet, capsule, liquid, dose or treatment schedule beyond the limitations inherited from claim 1.

Claim 5 covers oral administration in one of three formulation types:

Microemulsion
Soft gel
Solid dispersion

Claim 6 is limited to a microemulsion.

These claims can create protection around the delivery system rather than the active ingredient alone. They may become relevant if a generic or follow-on product uses an equivalent oral formulation and its label or product documentation identifies the claimed dosage form.

A formulation claim generally presents greater enforcement difficulty when the formulation is not visible from the product label. Discovery, manufacturing records, ANDA records and product testing may be required to establish infringement.

What FDA exclusivity protects Rydapt?

Rydapt received FDA approval for two broad disease categories:

Newly diagnosed FLT3-mutation-positive AML, in combination with chemotherapy.
Advanced systemic mastocytosis, including aggressive systemic mastocytosis and systemic mastocytosis with associated hematological neoplasm.[3]

The relevant regulatory protections are distinct from patent protection.

Protection	Approximate status
New chemical entity exclusivity	Five years from first FDA approval, subject to statutory exceptions
AML orphan-drug exclusivity	Seven years from AML approval
Systemic mastocytosis orphan-drug exclusivity	Seven years for the applicable orphan indication
Patent 8,222,244	Expected to run into March 2027, subject to official term calculation
Orange Book listing	Must be confirmed against the current FDA Orange Book entry

FDA exclusivity prevents certain abbreviated applications from being approved during the applicable period. It does not extend the patent term and does not independently prevent all competing clinical development.[5]

What is the Orange Book status of U.S. Patent 8,222,244?

Patent 8,222,244 has been associated with the Rydapt product and its AML method of use. FDA Orange Book listing status is legally important because it determines whether an ANDA applicant must address the patent through a Paragraph IV certification or may use another certification pathway.[2]

The practical consequences are:

A listed method-of-use patent can trigger a Paragraph IV certification.
A Paragraph IV notice can support Hatch-Waxman litigation.
A generic applicant may seek a section viii “skinny label” if it can omit the patented use while retaining noninfringing indications.
A skinny label is difficult where the patented indication is central to the product’s commercial use or where labeling, prescribing information or promotional conduct encourages the patented method.

The Orange Book does not itself determine infringement. It records FDA-listed patents and regulatory exclusivities. Infringement depends on the claims, the proposed product and the applicant’s labeling and conduct.

When does midostaurin lose patent exclusivity?

The principal patent risk date for the claimed AML use is expected to be in March 2027, based on the patent’s ordinary 20-year term measured from its earliest effective nonprovisional filing or priority framework.[1]

The exact expiration date must be read from the USPTO’s official patent-term calculation. Relevant variables include:

Patent-term adjustment.
Any terminal disclaimer.
Patent-term extension under 35 U.S.C. §156.
Continuation or divisional relationships.
Maintenance-fee status.
Any later judicial or administrative change.

Patent expiration does not necessarily produce immediate generic competition. FDA exclusivity, ANDA approval timing, litigation stays and formulation patents can delay or complicate launch.

Which companies could challenge the Rydapt patent estate?

Potential challengers include generic manufacturers that develop oral midostaurin products and file ANDAs. The public patent-risk analysis should focus on:

Teva Pharmaceuticals
Sandoz
Dr. Reddy’s Laboratories
Sun Pharma
Lupin
Cipla
Hikma
Other manufacturers developing oncology generics

A company seeking approval before patent expiration would generally assess:

Paragraph III certification, accepting delay until expiration.
Paragraph IV certification, asserting invalidity, unenforceability or noninfringement.
Section viii carve-out of the patented AML use.
Formulation design that avoids claims 5 and 6.
A label limited to an unpatented indication, if legally and commercially viable.

The most important litigation questions would concern claim construction for “deregulated FLT3 receptor tyrosine kinase activity,” the validity of the dosing language in claim 2, anticipation of the 225 mg regimen, and whether a proposed formulation falls within claims 5 or 6.

What patent litigation and settlement issues affect midostaurin?

A Paragraph IV notice can create a 45-day period for the patent owner to file suit and, if statutory requirements are met, a 30-month stay of FDA approval under the Hatch-Waxman framework.[6]

The principal settlement variables would include:

Authorized-generic rights.
Launch date before or after March 2027.
Restrictions on AML labeling.
Formulation-specific covenants.
Royalty or supply arrangements.
Treatment of systemic mastocytosis indications.
Allocation of invalidity and noninfringement risk.

No settlement can be inferred from the patent claims alone. A settlement would require review of the ANDA litigation docket, FDA Paragraph IV notices, court orders and any filed agreement.

How strong is the patent estate for midostaurin?

The patent estate is strongest where a competitor’s label expressly directs midostaurin use for FLT3-positive AML and uses an accused oral dosage form. It is weaker against a product that:

Avoids the patented AML indication.
Uses a different formulation.
Does not direct treatment of deregulated FLT3 AML.
Challenges the breadth or validity of claim 2.
Demonstrates that the claimed method was anticipated by prior clinical disclosures.

Strength assessment

Issue	Assessment
Chemical identity	Strongly defined, but the patent is not a broad composition-of-matter patent
AML indication	Commercially important and directly aligned with Rydapt’s approved use
FLT3 limitation	Narrows the claim but links it closely to the approved biomarker-defined population
Claim 2 regimen	Vulnerable wording because of “7 to 4,” “about” and “several”
225 mg dose	Narrow and poorly aligned with the approved 100 mg daily AML schedule
Oral route	Broad dependent claim with potential product-label relevance
Formulation claims	Potentially useful, but infringement may require product or manufacturing evidence
Generic exposure	Highest for a label directing use in FLT3-positive AML
Biosimilar exposure	Not applicable; midostaurin is a small-molecule drug

How does midostaurin compare with competing FLT3 inhibitors?

Midostaurin competes with other FLT3-directed therapies, but those products do not automatically infringe Patent 8,222,244 because the patent claims administration of midostaurin specifically.

Drug	Developer or marketer	Principal FLT3 use	Patent relationship
Midostaurin	Novartis	Newly diagnosed FLT3-mutated AML with chemotherapy	Directly implicated
Gilteritinib	Astellas	Relapsed or refractory FLT3-mutated AML	Separate molecule and patent estate
Quizartinib	Daiichi Sankyo	Newly diagnosed FLT3-ITD AML with chemotherapy	Separate molecule and patent estate
Crenolanib	Arog Pharmaceuticals and partners	Investigational or development-stage FLT3 use	Separate molecule and patent estate
Sorafenib	Bayer and others	Off-label or combination FLT3-related use	Separate molecule and patent estate

The competitive threat is therefore commercial rather than direct patent infringement. Gilteritinib and quizartinib can reduce midostaurin demand without practicing the patented method.

What generic launch scenarios exist?

Scenario 1: Launch after patent expiration

This is the lowest litigation-risk path. The applicant accepts the patent and times approval and launch after the applicable patent and exclusivity barriers end.

Scenario 2: Paragraph IV challenge

The applicant argues that Patent 8,222,244 is invalid or not infringed. The principal attack points are:

Prior-art disclosure of midostaurin in AML.
Prior-art disclosure of FLT3 deregulation.
Obviousness of treating FLT3-positive AML with midostaurin.
Indefiniteness of claim 2.
Lack of written description or enablement for broad regimen language.
Noninfringement based on dose, formulation or label differences.

Scenario 3: Section viii carve-out

The applicant omits the patented AML method from its labeling and seeks approval for another approved use, if that use is not separately protected. This strategy may have limited commercial value because AML is a central Rydapt indication.

Scenario 4: Formulation redesign

A generic may avoid microemulsion, soft-gel or solid-dispersion claims by using a conventional solid oral formulation. This does not avoid claim 1 or claim 4 if the label still directs oral midostaurin treatment for FLT3-deregulated AML.

Key Takeaways

U.S. Patent 8,222,244 is a midostaurin method-of-treatment patent, not the primary composition-of-matter patent.
Claim 1 targets AML characterized by deregulated FLT3 receptor tyrosine kinase activity.
The patent’s commercial center is the FLT3-positive AML indication corresponding to Rydapt.
Claim 3’s 225 mg daily dose does not match the FDA-approved AML dose of 100 mg per day.
Claims 5 and 6 add formulation protection but may require confidential product or manufacturing evidence for enforcement.
Claim 2 presents potential indefiniteness and written-description issues because of “7 to 4 times,” “about” and “several cycles.”
The expected patent expiration is in March 2027, subject to the USPTO’s official term calculation.
A generic filing before expiration would likely require a Paragraph IV strategy, a section viii carve-out or a post-expiration launch.
Gilteritinib and quizartinib compete commercially but do not directly practice the midostaurin claims.
Biosimilar analysis is inapplicable because midostaurin is a small-molecule drug.

FAQs About U.S. Patent 8,222,244 and Rydapt

Does Patent 8,222,244 cover all uses of midostaurin?

No. It covers specified methods involving AML with deregulated FLT3 activity. It does not, based on the quoted claims, cover every disease, dose, formulation or use of midostaurin.

Does the patent cover Rydapt’s 50 mg twice-daily AML regimen?

Claim 1 may cover the underlying method if all claim elements are met. Claim 3 specifically requires 225 mg daily and therefore does not correspond to the approved 50 mg twice-daily regimen.

Can a generic avoid the patent by using a tablet instead of a microemulsion?

That may avoid claims 5 and 6, but it would not necessarily avoid claims 1 or 4. A conventional tablet remains an oral administration method.

Is FLT3 mutation testing required to prove infringement?

Not necessarily. The claim requires AML characterized by deregulated FLT3 activity. Mutation testing is strong evidence, but the claim language may encompass other forms of abnormal FLT3 signaling depending on claim construction.

Are gilteritinib and quizartinib subject to Patent 8,222,244?

No. Those drugs are chemically different FLT3 inhibitors with separate patent estates. Their commercial use can compete with midostaurin without practicing the compound-specific claims of Patent 8,222,244.

References

United States Patent and Trademark Office. (2012). U.S. Patent No. 8,222,244, methods of treating acute myeloid leukemia.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2023). Rydapt (midostaurin) prescribing information. Novartis Pharmaceuticals Corporation.
35 U.S.C. § 112. Patentability requirements, including written description, enablement and definiteness.
21 U.S.C. § 355. New drug applications, abbreviated applications and regulatory exclusivity.
21 U.S.C. § 355(j). Abbreviated new drug applications, patent certifications and approval stays.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1441737	⤷ Start Trial	122018000038	Germany	⤷ Start Trial
European Patent Office	1441737	⤷ Start Trial	C01441737/01	Switzerland	⤷ Start Trial
European Patent Office	1441737	⤷ Start Trial	18C1012	France	⤷ Start Trial
Austria	335490	⤷ Start Trial
Australia	2006249245	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,222,244

Summary for Patent: 8,222,244